Life Sciences Tools and Services
Company Overview of Rubicon Genomics, Inc.
Rubicon Genomics, Inc. engages in the development and commercialization of sample-specific nucleic acid library preparation products for use in research and clinical testing on next-generation sequencing (NGS), microarray, and q-PCR platforms. The company creates molecular biology tools for genetic, epigenetic, and expression analysis of various samples to facilitate gene-based research, drug development, and diagnostics. Its products include ThruPLEX DNA-seq kits to generate DNA libraries with expanded multiplexing capability and diversity with lower duplication rates; PicoPLEX DNA-seq kits to streamline library preparation and PicoPLEX process used by IVF clinics for pre-implantation genet...
4743 Venture Drive
Ann Arbor, MI 48108
Founded in 2000
Key Executives for Rubicon Genomics, Inc.
Chairman, Chief Executive Officer and President
Co-Founder and Chief Scientific Officer
Vice President of Business Development
Compensation as of Fiscal Year 2015.
Rubicon Genomics, Inc. Key Developments
Rubicon Genomics, Inc. Adds Delonix Healthcare Pvt. Ltd and Biocena Ltd. as New Distributors
Jan 11 16
Rubicon Genomics, Inc. announced the addition of new distributors in India and Poland. The new distributors are Delonix Healthcare Pvt. Ltd. and Biocena Ltd.
Rubicon Genomics, Inc. Reports Sales Results for the Year 2015
Jan 11 16
Rubicon Genomics, Inc. reported sales results for the year 2015. For the year, the company reported a 40% increase in year-over-year sales in 2015.
Rubicon Genomics Announces Eurofins Scientific to Distribute its Suite of DNA Library Preparation Kits in U.S
Oct 29 15
Rubicon Genomics, Inc. announced an agreement with Eurofins Genomics for U.S. distribution of its DNA library preparation products, including the ThruPLEX DNA-seq kit and Rubicon's new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq has been optimized for cell-free DNA to enable the preparation of NGS libraries for liquid biopsies-the analysis of cell-free circulating DNA in plasma for diagnostic and prognostic applications in cancer and other conditions. Liquid biopsies can eliminate the need for invasive and costly tissue biopsies to detect biomarkers and other genetic mutations in tumors. They are expected to transform cancer screening, diagnostics and treatment and to replace many prenatal amniocentesis procedures. ThruPLEX Plasma-seq kits enable liquid biopsies by producing highly reproducible next-generation sequencing (NGS) libraries from small amounts of cell-free DNA in plasma, enabling accurate and informative results from samples that might otherwise be difficult or impossible to analyze. ThruPLEX Plasma-seq libraries are suitable for whole genome, whole exome and targeted gene sequencing. The performance of the ThruPLEX Plasma-seq kit has been validated by researchers at the Karolinska Institute in Sweden and Cancer Research UK (CRUK). ThruPLEX Plasma-seq can now be easily automated for high throughput applications on Beckman Coulter's Biomek FXP Liquid Handling Workstation, a leading automated solution for laboratories worldwide. ThruPLEX DNA-seq works with as little as 50 picograms of DNA and is especially efficient for challenging specimens. The entire workflow is performed in a single tube or well in about two hours and requires no purification steps or sample transfers. ThruPLEX DNA-seq produces uniform coverage and improves molecular complexity, yielding highly reproducible sequencing results.
Similar Private Companies By Industry
Recent Private Companies Transactions
July 15, 2015
Most Searched Private Companies
Sponsored Financial Commentaries